In vivo imaging neurotransmitter function

Summary

This article gives an overview of those small animal imaging studies which have been conducted on neurotransmitter function in the rat 6-hydoxydopamine (6-OHDA) model of Parkinson’s disease, and discusses findings with respect to the outcome of clinical studies on Parkinsonian patients.

Zusammenfassung

Diese Arbeit gibt eine Übersicht über die bildgebenden Untersuchungen zur Neurotransmitterfunktion, die am 6-Hydroxydopamin- Modell der Ratte durchgeführt wurden. Die Befunde werden im Hinblick auf die Ergebnisse klinischer Studien an Patienten mit Morbus Parkinson diskutiert.

Keywords

Parkinson's disease - PET - SPECT - dopamine - 6-hydroxydopamine model - small animal imaging

Schlüsselwörter

Morbus Parkinson - PET - SPECT - Dopamin - 6-Hydroxydopamin-Modell - Kleintierbildgebung

• References

• 1 Björklund LM, Sanchez-Pernaute R, Chung S. et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002; 99: 2344-2349.
• 2 Bohnen NI, Albin RL, Koeppe RA. et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006; 26: 1198-1212.
• 3 Booij J, de Bruin K, Habraken JB. et al. Imaging of dopamine transporters in rats using high-resolution pinhole single-photon emission tomography. Eur J Nucl Med Mol Imaging 2002; 29: 1221-1224.
• 4 Brotchie JM. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 2003; 3: 54-61.
• 5 Brownell AL, Livni E, Galpern W, Isacson W. In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. Ann Neurol 1998; 43: 387-390.
• 6 Casteels C, Vermaelen P, Nuyts J. et al. Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. J Nucl Med 2006; 47: 1858-1866.
• 7 Casteels C, Lauwers E, Baitar A. et al. In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease. Brain Res 2010; 1316: 153-262.
• 8 Caudle WM, Zhang J. Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol 2009; 220 (02) 30-33.
• 9 Chen YCI, Galpern WR, Brownell AL. et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 1997; 38: 389-398.
• 10 Chen YI, Brownell AL, Galpern W. et al. Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. Neuroreport 1999; 10: 2881-2886.
• 11 Cicchetti F, Brownell AL, Williams K. et al. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002; 15: 991-998.
• 12 Collantes M, Penuelas I, Alvarez-Erviti L. et al. Use of ¹¹C-(+)-alpha -dihydrotetrabenazine for the assessment of dopaminergic innervation in animal models of Parkinson's disease. Rev Esp Med Nucl 2008; 27: 103-111.
• 13 Cumming P, Ase A, Diksic M. et al. Metabolism and blood-clearanceof L-3,4-dihydroxy-[³H]phenylalanine [³H]DOPAand 6-{¹⁸F]fluoro-L-DOPA in the rat. Biochem Pharmacol 1995; 50: 943-946.
• 14 Duty S. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br J Pharmacol 2010; 161: 271-287.
• 15 Ferré S, Fuxe K. Dopamine denervation leads to an increase in the intramembrane interactions between adenosine A₂ and dopamine D₂ receptors in the neostriatum. Brain Res 1992; 595: 124-130.
• 16 Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Disord 2009; 24: 1255-1266.
• 17 Honer M, Hengerer B, Blagoev M. et al. Comparison of [¹⁸F]FDOPA, [¹⁸F]FMT and [¹⁸F]FECNT for imaging dopaminergic neurotransmission in mice. Nucl Med Biol 2006; 33: 607-614.
• 18 Hume SP, Opacka-Juffry J, Myers R. et al. Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum quantified using PET. Synapse 1995; 21: 45-53.
• 19 Hume SP, Lammertsma AA, Myers R. et al. The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. J Neurosci Meth 1996; 67: 103-112.
• 20 Inaji M, Okauchi T, Ando K. et al. Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res 2005; 1064: 136-145.
• 21 Inaji M, Yoshizaki T, Okauchi T. et al. In vivo PET measurements with [¹¹C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDA-lesioned rats. Cell Transplant 2005; 14: 655-663.
• 22 Jackson J, Chapon C, Jones W. et al. In vivo multimodal imaging of stem cell transplantation in a rodent model of Parkinson's disease. J Neurosci Methods 2009; 183: 141-148.
• 23 Jordan S, Eberling JL, Bankiewicz KS. et al. 6-[18F] fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates. Brain Res 1997; 750: 264-276.
• 24 Klein RL, Dayton RD, Terry TL. et al. PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models. Brain Res 2009; 1259: 113-122.
• 25 Kuhar MJ, Couceyro PR, Lambert PD. Catecholamines. Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Whler MD. Basic Neurochemistry - Molecular, Cellular and Medical Aspects.. Baltimore: Lippincott, Williams & Wilkins; 1998: 243-261.
• 26 Nguyen TV, Brownell AL, Chen YCI. et al. Detection of the effects of dopamine receptor sensitivity using pharmacological MRI and correlations with PET. Synapse 2000; 36: 57-65.
• 27 Nikolaus S, Huston JP, Körber B. et al. Pretreatment with neurokinin substance P but not with cholecystokinin-8S can alleviate functional deficits of partial nigrostriatal 6-hydroxydopamine lesion. Peptides 1997; 18: 1161-1168.
• 28 Nikolaus S, Huston JP, Schwarting RKW. Pretreatment with fragments of substance-P or with cholecystokinin differentially affects revovery from subtotal nigrostriatal 6-hydroxydopamine lesion. Neural Plast 1999; 6: 77-89.
• 29 Nikolaus S, Larisch R, Beu M. et al. Imaging of striatal dopamine D₂ receptors with a PET system for small laboratory animals in comparison with storage phosphor autoradiography: a validation study with [¹⁸F]N-methyl-benperidol. J Nucl Med 2001; 42: 1691-1661.
• 30 Nikolaus S, Larisch R, Beu M. et al. Bilateral increase in striatal dopamine D₂ receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET. Eur J Nucl Med Mol Imaging 2003; 30: 390-395.
• 31 Nikolaus S, Larisch R, Beu M. et al. In vivo measurement of D₂ receptor density and affinity for ¹⁸F-(3-N-methyl)benperidol in the rat striatum with a PET system for small laboratory animals. J Nucl Med 2003; 44: 618-624.
• 32 Nikolaus S, Beu M, Wirrwar A. et al. The contribution of small animal positron emission tomography to the neurosciences - a critical evaluation. Rev Neurosci 2004; 15: 131-156.
• 33 Nikolaus S, Wirrwar A, Antke C. et al. Stand der Kleintierbildgebung mit hochauflösender SPECT. Nuklearmedizin 2005; 6: 257-266.
• 34 Nikolaus S, Antke C, Kley K. et al. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev Neurosci 2007; 18: 439-472.
• 35 Nikolaus S, Larisch R, Beu M. et al. Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals. Rev Neurosci 2007; 18: 473-505.
• 36 Nikolaus S, Antke C, Müller HW. In vivo imaging of synaptic function in the central nervous system. I. Movement disorders and dementia. Behav Brain Res 2009; 204: 1-31.
• 37 Nikolaus S, Antke C, Müller HW. In vivo imaging of synaptic function in the central nervous system. II. Mental and affective disorders. Behav Brain Res 2009; 204: 32-66.
• 38 Nikolaus S, Beu M, Antke C, Müller HW. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders - Results from in vivo imaging studies. Rev Neurosci 2010; 21: 119-139.
• 39 Opacka-Juffry J, Ashworth S, Hume SP. et al. GDNF protects against 6-hydroxydopamine lesion: in vivo study with microdialysis and PET. Neuroreport 1995; 7: 348-352.
• 40 Opacka-Juffry J, Ashworth S, Sullivan AM. et al. Lack of permanent nigrostriatal dopamine deficit following 6-hydroxydopamine injection into the rat striatum. J Neural Transm 1996; 103: 1429-1434.
• 41 Pellegrino D, Cicchetti F, Wang X. et al. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats. J Nucl Med 2007; 48: 1147-1153.
• 42 Pritzel M, Huston JP, Sarter M. Behavioral and neuronal reorganization after unilateral substantia nigra lesions: evidence for increased interhemispheric nigrostriatal projections. Neuroscience 1983; 9: 879-888.
• 43 Santiago RM, Barbieiro J, Lima MMS. et al. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiat 2010; 34: 1140-1114.
• 44 Scherfler C, Donnemiller E, Schocke M. et al. Evaluation of striatal dopamine transporter function in rats by in vivo beta-[¹²³I]CIT pinhole SPECT. Neuroimage 2002; 17: 128-141.
• 45 Schramm NU, Ebel G, Engeland U. et al. High-resolution SPECT using multipinhole collimation. IEEE Trans Nucl Sci 2003; 50: 315-320.
• 46 Schwarting RKW, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996; 50: 275-331.
• 47 Sossi V, Holden JE, Topping GJ. et al. In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. J Cereb Blood Flow Metab 2007; 27: 1407-1415.
• 48 Sossi V, Dinelle K, Topping GJ. et al. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J Neurochem 2009; 109: 85-92.
• 49 Sossi V, Dinelle K, Schulzer M. et al. Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur J Nucl Med Mol Imaging 2010; 37: 2364-2370.
• 50 Strome EM, Cepeda IL, Sossi V, Doudet DJ. Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol Imaging Biol 2006; 8: 292-299.
• 51 Sullivan AM, Opacka-Juffry J, Blunt SB. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo . Eur J Neurosci 1998; 10: 57-63.
• 52 Sun W, Sugiyama K, Fang X. et al. Different striatal D2-like receptor function in an early stage after unilateral striatal lesion and medial forebrain bundle lesion in rats. Brain Res 2010; 1317: 227-235.
• 53 Wang JL, Shunichi O, Parhi AK. et al. In vivo studies on SERT-selektive [¹⁸F]FPBM and VMAT2-selective [¹⁸F]AV-133 radiotracers in a rat model of Parkinson's disease. Nucl Med Biol 2010; 37: 479-486.
• 54 Wu C, van der Have F, Vastenhouw B. et al. Absolute quantitative total-body small-animal SPECT with focusing pinholes. Eur J Nucl Med Mol Imaging 2010; 37: 2127-2135.
• 55 Zhu A, Wang X, Yu M. et al. Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies. J Cereb Blood Flow Metab 2007; 27: 1623-1631.